Skip to content
Clinical Trials – home

Migraine

  • 48 clinical trials
Quick filters

48 Clinical trials

Migraine

Recruiting

A study to evaluate the effect of rimegepant in patients with migraine and obesity

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Rimegepant
  • Sponsor:Konvent Der Barmherzigen Brueder

Migraine

Recruiting

A Study Testing Cabergoline to Prevent and Treat Episodic Migraine in Patients with Recurring Migraine Headaches

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Cabergoline
  • Sponsor:Region Midtjylland

Migraine

Recruiting

Study on Eptinezumab for Migraine: Understanding How It Works and Finding Patient Response Markers for Migraine Sufferers

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Eptinezumab
  • Sponsor:Ospedale San Raffaele S.r.l.

Migraine

Recruiting

Study on the Safety and Effectiveness of Atogepant for Preventing Chronic Migraine in Children Aged 12 to 17

Investigational
Countries:DenmarkDenmark
  • Participants:0–17 years
  • Substances:Atogepant
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Migraine

Recruiting

Study on Reducing Chronic Migraine Days with CGRP Antibodies and Botulinum Toxin A in Adults Aged 18-70

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Erenumab
  • Sponsor:Oslo University Hospital HF

Migraine

Recruiting

Study on Sumatriptan and Rimegepant for Treating Nitroglycerin-Induced Headaches in Patients with Episodic Migraine

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Isosorbide Dinitrate
  • Sponsor:Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
See all trials →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.